Search This Blog

Thursday, September 3, 2026

Rothschild & Co Redburn downgrades Moderna to Sell from Neutral

 

Rothschild & Co Redburn downgrades Moderna to Sell from Neutral, raises price target to $81 on intismeran cancer vaccine concerns

  • Broker says post-Phase 3 melanoma trial rally overestimates intismeran cancer vaccine’s broader tumor-type potential.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)